Risankizumab for Ulcerative Colitis
2024 · JAMA · 98 citations
https://doi.org/10.1001/jama.2024.12414
Q
Qian Cao
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
113
Papers
987
Citations
16
h-index
26
i10-index
Qian Cao is an academic researcher from Wannan Medical College. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Eosinophilic Esophagitis. The author has an h-index of 16, co-authored 97 publications.
ORCID: 0000-0001-7938-7532Papers by this author
worksGuselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
2023 · Gastroenterology · 88 citations
https://doi.org/10.1053/j.gastro.2023.08.038
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
2024 · The Lancet · 76 citations
https://doi.org/10.1016/s0140-6736(24)01762-8
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study
2025 · Gastroenterology · 33 citations
https://doi.org/10.1053/j.gastro.2025.02.033
Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice
2025 · Nature Communications · 22 citations
https://doi.org/10.1038/s41467-025-57603-1
<scp>XAF1</scp> prevents hyperproduction of type I interferon upon viral infection by targeting <scp>IRF7</scp>
2022 · EMBO Reports · 16 citations
https://doi.org/10.15252/embr.202255387
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat